Halozyme Therapeutics (HALO) Common Equity (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Common Equity of $219.6 million for Q1 2026, down 54.46% year-over-year from $482.3 million in Q1 2025, and up 349.94% quarter-over-quarter from $48.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Common Equity (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Common Equity for 17 consecutive years, with $219.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 54.46% year-over-year to $219.6 million; the TTM figure through Mar 2026 stood at $219.6 million (down 54.46% YoY), while the FY2025 annual figure was $48.8 million, down 86.58% from the prior year.
- Common Equity advanced to $219.6 million in Q1 2026 per HALO's latest filing, from $48.8 million in the prior quarter.
- Across five years, Common Equity topped out at $503.9 million in Q3 2025 and bottomed at $48.8 million in Q4 2025.
- Historically, Common Equity has averaged $249.5 million across 5 years, with a median of $249.2 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity jumped 334.11% — and 2025, when it tumbled 86.58%.
- Halozyme Therapeutics' Common Equity stood at $169.8 million in 2022, then tumbled by 50.64% to $83.8 million in 2023, then surged by 334.11% to $363.8 million in 2024, then sank by 86.58% to $48.8 million in 2025, then soared by 349.94% to $219.6 million in 2026.
- Business Quant data shows HALO's Common Equity at $219.6 million in Q1 2026, $48.8 million in Q4 2025, and $503.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 143.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143.54 Mn |
| Mar 31, 2026 | 219.64 Mn |
| Dec 31, 2025 | 48.81 Mn |
| Sep 30, 2025 | 503.92 Mn |
| Jun 30, 2025 | 332.75 Mn |
| Mar 31, 2025 | 482.27 Mn |
| Dec 31, 2024 | 363.82 Mn |
| Sep 30, 2024 | 452.70 Mn |
| Jun 30, 2024 | 289.42 Mn |
| Mar 31, 2024 | 177.81 Mn |
| Dec 31, 2023 | 83.81 Mn |
| Sep 30, 2023 | 249.18 Mn |
| Jun 30, 2023 | 151.03 Mn |
| Mar 31, 2023 | 65.85 Mn |
| Dec 31, 2022 | 169.80 Mn |
| Sep 30, 2022 | 96.99 Mn |
| Jun 30, 2022 | 293.17 Mn |
| Mar 31, 2022 | 260.26 Mn |
| Dec 31, 2021 | 196.95 Mn |
| Sep 30, 2021 | 281.67 Mn |